GLP‑1 Weight‑Loss Drugs Cut Krispy Kreme Sales and Shift Retail Spending

Widespread use of GLP‑1 receptor agonists such as Ozempic, now taken by roughly 11 % of U.S. adults, is suppressing cravings for sugary and fatty foods. The resulting decline in demand for traditional doughnuts has hit Krispy Kreme, which reports lower foot traffic, thinner margins and a need to diversify beyond its core pastry menu.

Industry analysts note that food retailers are adapting by adding higher‑protein, lower‑calorie items, while competitors lean into higher‑margin beverages. The broader impact extends to the hospitality sector, where restaurant sales are falling as diners order smaller portions. At the same time, reduced food spending is boosting brick‑and‑mortar apparel sales, offering a modest offset for physical retailers.

These trends signal a reshaping of consumer baskets toward healthier, portion‑controlled choices, challenging legacy food chains and prompting strategic pivots across the retail landscape.